Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis

Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis - Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035522

Enrollment

Registered

2019-01-11

Start date

2019-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Placenta extract ( JBP porcine 100: 350mg a capsule), 6 capsules per day, 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients over the age of twenty with Child grade B liver cirrhosis 2) Consent is obtained in writing

Exclusion criteria

Exclusion criteria: 1)patients hypersensitive to placenta 2)patients with uncontrolled hepatoma 3) complicated other malignancy and survival prognosis is one year or less 4) psychosomatic disorder or neurological disorder except for hepatic encephalopathy 5) severe infection example for tuberculosis

Design outcomes

Primary

Measure	Time frame
Estimation of general fatigue by questionnaire before, 12, 24 weeks after beginning administration of placenta extract and 12 weeks after end of administration	—

Secondary

Measure	Time frame
Estimation of liver disease specialized QOL questionnaire, total bilirubin, total protein, serum albumin annmonia, ferritin, prothrombin time, AST, ALT, BUN, serum creatinine, free fatty acid, IRI, blood suger, Na, K, Cl, hyaluronic acid, type IV collagen 7s, M2BPGi, hepcidin, BMP receptor binging factor, check sheet for muscle cramp (visual analogue scale), total body water, total body muscle volume, total body fat volume estimated body composition analyzer and grip before, 12, 24 weeks after beginning administration of placenta extract and 12 weeks after end of administration	—

Measure

Time frame

Estimation of liver disease specialized QOL questionnaire, total bilirubin, total protein, serum albumin annmonia, ferritin, prothrombin time, AST, ALT, BUN, serum creatinine, free fatty acid, IRI, blood suger, Na, K, Cl, hyaluronic acid, type IV collagen 7s, M2BPGi, hepcidin, BMP receptor binging factor, check sheet for muscle cramp (visual analogue scale), total body water, total body muscle volume, total body fat volume estimated body composition analyzer and grip before, 12, 24 weeks after beginning administration of placenta extract and 12 weeks after end of administration

—

Countries

Japan

Contacts

Public ContactHiroshi Tobita

Shimane University Hospital Hepatology

ht1020@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026